Version history

{
  "session_id": "sess_SDA-2026-04-04-gap-20260404-microglial-priming-early-ad_20260412-073015",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "support",
  "content": "\n\n# Domain Expert Evaluation: Microglial Priming Hypotheses in Alzheimer's Disease\n\n---\n\n## Executive Summary\n\nThe field of microglial biology has reached an inflection point where translational momentum is substantial but mechanistic specificity remains the critical bottleneck. Your Theorist has constructed a sophisticated framework around TREM2-ICD nuclear signaling, but I must be direct: the evidence base, while mechanistically compelling, has significant gaps that will determine whether this hypothesis translates to human therapeutics within the next decade or remains a cell biological curiosity. Let me address your questions systematically.\n\n---\n\n## Question 1: Hypotheses with Highest Translational Potential\n\nGiven the current Alzheimer's clinical landscape—dominated by anti-amyloid monoclonal antibodies with limited neuroinflammatory targets, ongoing TREM2 agonism trials, and emerging metabolic modulators—I identify the following priorities:\n\n### 1.1 TREM2 Pathway Agonism (Highest Immediate Translational Potential)\n\n**Rationale:** This has already crossed the translational gap. AL002 (Alector/AbbVie) and NLY023 (NodThera) are in Phase II trials. The theorized TREM2-ICD mechanism, if validated, would inform patient stratification and combination strategies rather than constitute the primary therapeutic approach itself.\n\n**Current status:**\n- AL002 Phase II (INVOKE-2) enrolled prodromal-mild AD with biomarker-confirmed amyloid\n- Primary endpoint: CDR-SB at 96 weeks\n- Biomarker substudies include CSF sTREM2, TSPO-PET, and plasma p-tau217\n- Safety profile to date shows no dose-limiting toxicities related to microglial suppression\n\n**Translational fit:** Strong. TREM2 agonists work upstream of the priming cascade—sustained activation may prevent the ICD-dependent locked state or redirect DAM signatures toward homeostatic function.\n\n---\n\n### 1.2 Complement-Mediated Synaptic Pruning as Progression Driver\n\n**Rationale:** The complement cascade (C1q, C3, CR3) represents a downstream effector of microglial priming with substantial human genetic support (C4A copy number variation, CR1) and a therapeutic angle distinct from TREM2.\n\n**Evidence base:**\n- C1q",
  "tokens_used": "547"
}